Skip to content

Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage

Remote Ischemic Preconditioning to Ameliorate Delayed Ischemic Neurological Deficit After Aneurysmal Subarachnoid Hemorrhage: a Safety and Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02411266
Acronym
PreLIMBS
Enrollment
57
Registered
2015-04-08
Start date
2008-07-30
Completion date
2020-12-08
Last updated
2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Preconditioning

Brief summary

The purpose of this study is to learn about protecting the brain from dangerous low blood flow.

Interventions

application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with aneurysmal subarachnoid hemorrhage whose initial angiogram show an aneurysm and patients with clipped aneurysm will be eligible for enrollment. * Patients will be enrolled within 96 hours of bleeding onset, if informed consent is obtained from the participant or health care proxy, as appropriate.

Exclusion criteria

* Hunt Hess Scale \> 4 * Inability to undergo limb preconditioning due to local wound or tissue breakdown, history of peripheral extremity vascular disease or patient discomfort. * Inability to obtain informed consent from the patient or a health care proxy. * Ankle-brachial index \< 0.7 * Inability to start limb preconditioning within 4 days of bleeding. * Inability to precondition a leg that is not-plegic (that is preserved anti- gravity strength) and has not been accessed for catheter angiography * Age\<18 years * Pregnant women * Prisoners

Design outcomes

Primary

MeasureTime frameDescription
Safety Outcomes 1 - number of patients who develop deep vein thrombosis and thromboembolism90 daysThe number of patients who develop deep vein thrombosis and thromboembolism in the treatment and control group.
Safety Outcome 2 - number of patients who develop neurovascular injury90 daysThe number of patients who develop neurovascular injury in the treatment and control group.
Safety Outcome 3 - number of patients who cannot tolerate the intervention due to discomfort90 daysThe number of patients who cannot tolerate the intervention due to discomfort.
Safety Outcome 4 - number of patients with cardiovascular events90 daysThe number of patients with cardiovascular events \[defined as hypotension, myocardial ischemia\]

Other

MeasureTime frameDescription
Clinical Outcome - number of patients with a good modified Rankin Scale, defined as less than 290 daysThe number of patients with a good modified Rankin Scale, defined as less than 2, in the control and intervention group.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026